VANCOUVER, BC, Feb. 18, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company“), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that the Company is expanding its pre-clinical program to develop a novel diagnostic and treatment approach to fragile X syndrome (FXS), a persistent unmet medical need.


Previous articleMarkets for Feb 17: EHVVF +17.85%, MSET +15.04%, NM +8.93%
Next articleMindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company